

**Media Contact:**

Christina Aplington  
Ballou PR for HRA Pharma  
+33 (0)1 42 22 24 10  
[christina@balloupr.com](mailto:christina@balloupr.com)

## **HRA Pharma Named Finalist for the 2009 Scrip Awards and the 2009 Clinical Research Excellence Awards**

**Paris, France – September 18, 2009** – HRA Pharma ([www.hra-pharma.com](http://www.hra-pharma.com)), a privately-held European pharmaceutical company that designs products, devices and supporting services in reproductive health and endocrinology, has been named a finalist in two award competitions, the 2009 Scrip Awards and the 2009 Clinical Research Excellence Awards, in recognition of its research and development of ellaOne® (ulipristal acetate), its new generation emergency contraception.

Now in its 5<sup>th</sup> year, the Scrip Awards recognize the contribution of pharmaceutical and biotech companies to the improvement of healthcare worldwide. HRA Pharma was shortlisted in the category “Best New Drug” for ellaOne (ulipristal acetate). The winner will be announced at an awards ceremony on November 18<sup>th</sup> in London.

The Clinical Research Excellence Awards recognize corporate and individual excellence in clinical research, which involves partnerships between sponsors, CROs and investigators and their ability to communicate with each other and to the patients in their care. HRA Pharma was shortlisted in the category “Clinical Research Team of the Year” for the ellaOne (ulipristal acetate) team. The winner will be announced at an awards ceremony on October 20<sup>th</sup> in London.

Both awards are organized by Informa Healthcare and entries were judged by an independent panel of senior industry experts from across the globe.

###

### **About HRA Pharma**

HRA Pharma is an emerging, privately-held European pharmaceutical company that designs products, devices and supporting services in niche areas of health and makes them available to doctors and patients worldwide. The company targets therapeutic gaps in the areas of reproductive health and endocrinology, and uses innovative marketing solutions and socially-conscious programs, such as contraception education in developing countries, to promote healthy management of drugs and diseases. A pioneer in emergency contraception, its product NorLevo was the first emergency contraceptive based on one type of progesterone to be approved for sale by health authorities. Headquartered in Paris, France and with offices in Bochum, Germany and London, UK, HRA Pharma has built a strong network of R&D, manufacturing, distribution and NGO partners which enables it to satisfy critical patient needs and improve patient health in over 50 countries across the globe. Visit [www.hra-pharma.com](http://www.hra-pharma.com) for more information.